|
WO2017040304A1
(en)
|
2015-08-28 |
2017-03-09 |
Cornell University |
Malt1 inhibitors and uses thereof
|
|
WO2017081641A1
(en)
*
|
2015-11-13 |
2017-05-18 |
Novartis Ag |
Novel pyrazolo pyrimidine derivatives
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
EP3592731A4
(en)
*
|
2017-03-08 |
2020-10-07 |
Cornell University |
MALT1 INHIBITORS AND THEIR USES
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
CN111278816B
(zh)
|
2017-09-04 |
2024-03-15 |
C4医药公司 |
二氢喹啉酮
|
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
BR112020013285A2
(pt)
|
2017-12-28 |
2020-12-01 |
The General Hospital Corporation |
direcionamento do complexo de sinalossoma cbm que induz células t reguladoras a atingirem o microambiente tumoral
|
|
JP2021519337A
(ja)
|
2018-03-26 |
2021-08-10 |
シー４ セラピューティクス， インコーポレイテッド |
Ｉｋａｒｏｓの分解のためのセレブロン結合剤
|
|
ES2965494T3
(es)
|
2018-04-12 |
2024-04-15 |
Bayer Ag |
Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}benzamida y los correspondientes derivados de piridina-carboxamida como plaguicidas
|
|
EP3781156A4
(en)
|
2018-04-16 |
2022-05-18 |
C4 Therapeutics, Inc. |
SPIROCYCLIC COMPOUNDS
|
|
EA202092248A1
(ru)
|
2018-04-23 |
2021-02-04 |
Селджин Корпорейшн |
Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
|
|
SG11202010068VA
(en)
|
2018-04-25 |
2020-11-27 |
Bayer Ag |
Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CN110615779B
(zh)
*
|
2018-06-20 |
2023-03-24 |
上海科技大学 |
制备来那度胺衍生物的方法
|
|
CN113038948B
(zh)
|
2018-11-28 |
2024-07-12 |
武田药品工业株式会社 |
杂环化合物
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
CN113557235B
(zh)
|
2019-03-06 |
2025-08-08 |
C4医药公司 |
用于药物治疗的杂环化合物
|
|
US12233356B2
(en)
|
2019-03-21 |
2025-02-25 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
MX2021011242A
(es)
|
2019-03-21 |
2022-01-19 |
Codiak Biosciences Inc |
Conjugados de vesícula extracelular y usos de estos.
|
|
US20220372017A1
(en)
*
|
2019-06-24 |
2022-11-24 |
Dana-Farber Cancer Institute, Inc. |
Hck degraders and uses thereof
|
|
TWI862634B
(zh)
|
2019-07-23 |
2024-11-21 |
德商拜耳廠股份有限公司 |
作為殺蟲劑之新穎雜芳基三唑化合物（二）
|
|
BR112022006791A2
(pt)
|
2019-10-09 |
2022-06-28 |
Bayer Ag |
Novos compostos heteroaril-triazol como pesticidas
|
|
WO2021127586A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase degraders and methods of use thereof
|
|
US20240018157A1
(en)
*
|
2019-12-27 |
2024-01-18 |
Schrödinger, Inc. |
Cyclic compounds and methods of using same
|
|
US20230312639A1
(en)
*
|
2020-04-23 |
2023-10-05 |
University Of Iowa Research Foundation |
Gper proteolytic targeting chimeras
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
EP4163280A4
(en)
|
2020-05-27 |
2024-06-05 |
Takeda Pharmaceutical Company Limited |
Method for producing heterocyclic compound
|
|
EP4168441A4
(en)
*
|
2020-06-17 |
2024-07-10 |
Dana-Farber Cancer Institute, Inc. |
Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system
|
|
WO2021262969A1
(en)
|
2020-06-24 |
2021-12-30 |
The General Hospital Corporation |
Materials and methods of treating cancer
|
|
US20240241020A1
(en)
|
2020-09-23 |
2024-07-18 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
US20230414629A1
(en)
*
|
2020-11-12 |
2023-12-28 |
Monopteros Therapeutics, Inc. |
Materials and methods of treating cancer
|
|
WO2022152821A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
|
CN116762012A
(zh)
*
|
2021-01-29 |
2023-09-15 |
欧陆迪斯卡沃爱克斯公司 |
分子胶筛选测定及其实施方法
|
|
AU2022425324A1
(en)
|
2021-12-30 |
2024-05-30 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Tricyclic derivative inhibitor, preparation method therefor, and application thereof
|
|
JP2025503727A
(ja)
*
|
2022-01-18 |
2025-02-04 |
オーリジーン オンコロジー リミテッド |
Ｍａｌｔ－１阻害剤としての置換二環式複素環関連出願の相互参照 この出願は、２０２２年１月１８日に提出されたインド仮特許出願第２０２２４１００２８５９号に対する優先権を主張する。この仮出願の全内容は、参照により本明細書に組み込まれる。
|
|
WO2023143249A1
(zh)
*
|
2022-01-28 |
2023-08-03 |
上海齐鲁制药研究中心有限公司 |
靶向malt1的蛋白降解化合物
|
|
US20250381181A1
(en)
|
2022-02-02 |
2025-12-18 |
Ono Pharmaceutical Co., Ltd. |
Cancer treatment agent including malt1 inhibiting drug as active ingredient
|
|
EP4482497A2
(en)
*
|
2022-02-25 |
2025-01-01 |
Tegid Therapeutics, Inc. |
Protacs of malt1
|
|
AU2023283735A1
(en)
|
2022-06-06 |
2024-10-31 |
C4 Therapeutics, Inc. |
Bicyclic-substituted glutarimide cereblon binders
|